drugset / Trial / NCT05972135
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
Timeline
- Start
- 2023-10-23
- Primary completion
- 2027-08
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | — | Oral |
| Subject | Talquetamab | Monoclonal antibody | — | Subcutaneous |
| Subject | Teclistamab | Monoclonal antibody | — | Subcutaneous |
| Subject | Tocilizumab | Monoclonal antibody | — | — |